

FDA Launches Drug-Safety Surveillance System

BY MARY ELLEN SCHNEIDER
New York Bureau

The Food and Drug Administration has developed a new national electronic surveillance system that will allow it to search and analyze claims data and other clinical databases for possible postmarket adverse events for drugs and medical devices.

The Sentinel Initiative is designed to bring safety concerns from approved drugs and other medical products to the FDA's attention faster than the traditional MedWatch adverse event reporting system alone.

"We are moving from a reactive dependence on voluntary reporting of product safety concerns to a proactive surveillance of medical products that are currently on the market," Health and Human Services Secretary Mike Leavitt said during a press conference to announce the initiative. "The result will be much-improved safety and protections for the American people."

During the first phase of the project, the FDA will rely on Medicare data. As part of a pilot collaboration with the Centers for Medicare and Medicaid Services, FDA officials will use the Sentinel system to query Medicare Part D prescription drug claims data, which will be linked to Medicare inpatient and outpatient claims data. The Part D database currently holds information on medications used by more than 25 million beneficiaries, according to Health and Human Services.

The FDA will begin to look into the

data in 30 days, following the publication of a final regulation that will allow federal agencies, states, and academic researchers to use claims data from the Part D program for safety research and quality initiatives.

In the future, FDA officials hope to be able to query data from other government agencies, such as the Department of Defense and the Department of Veterans Affairs, as well as from large private health plans, said Dr. Andrew C. von Eschenbach,

FDA commissioner. He added that the Sentinel Initiative includes patient privacy protections. The system queries existing databases without actually acquiring the data. Essentially, the system asks questions and gets answers without identifying patient information.

The Sentinel system will work in conjunction with the existing FDA surveillance systems. For example, if the FDA receives a report of an adverse event following the use of a drug, officials will

be able to query data on a large number of subjects who have taken the drug. And, in the future, agency officials may even be able to compare data from patients taking the drug with a control group of similar patients who have not taken the drug. This will allow FDA officials to give physicians better information about what particular groups of patients may be at higher risk for a specific adverse event, said Dr. Janet Woodcock, director of FDA's Center for Drug Evaluation and Research. ■

INDEX OF ADVERTISERS

Bayer HealthCare, LLC	
Flintstones	3
Braintree Laboratories, Inc.	
AXID	25-26
Del Pharmaceuticals	
Orajel	14
Dermik Laboratories, Inc.	
BenzaClin	37-38
Galderma Laboratories, L.P.	
Differin	15-16
GlaxoSmithKline	
Altabax	8a-8b
Merck & Co., Inc.	
RotaTeq	10-12
Ortho McNeil-Janssen Pharmaceuticals, Inc.	
Concerta	12a-12b
PharmaDerm	
Cutivate	21-22
Sanofi-Pasteur, Inc.	
Adacel	27-28
Pentacel	44
Schering-Plough HealthCare Products, Inc.	
Coppertone	19
Sepracor Inc.	
Alvesco	5
Omnaris	32a-32b, 33
Shire US, Inc.	
Vyvance	22a-22d, 35-36
Shriners Hospitals for Children	
Corporate	6
Stiefel Laboratories, Inc.	
Verdeso	31-32
UCB, Inc. and sanofi-aventis U.S., LLC	
Xyzal	39-40
Unilever	
all Free Clear	17
Dove	29



Talk to your patients about
acne treatment—and the PUMP that delivers...

breakout performance

- ◆ 2 weeks to clearer skin^{1*}
- ◆ The only FDA-approved topical clindamycin/benzoyl peroxide combination acne treatment that significantly reduces both inflammatory and non-inflammatory lesions²

GET THEM
pumped!



Write "BenzaClin® PUMP 50g"!

BenzaClin^{topical gel}
clindamycin 1% - benzoyl peroxide 5% gel

* Visible results seen at Week 2 in two pivotal trials. Individual results may vary.

References: 1. Data on file, Dermik Laboratories. 2. BenzaClin® Prescribing Information, Dermik Laboratories; 2007.

BenzaClin® Topical Gel is indicated for the treatment of acne vulgaris.

Important Safety Information: BenzaClin® is well tolerated. Adverse events reported in clinical trials include dry skin (12%), application site reaction (3%), pruritus (2%), peeling (2%), erythema (1%), and sunburn (1%). BenzaClin® Topical Gel is contraindicated in those individuals who have shown hypersensitivity to any of its components or to lincomycin. BenzaClin® is also contraindicated in those having a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. Diarrhea, bloody diarrhea, and pseudomembranous colitis have been reported with topical clindamycin. Discontinuation is recommended if significant diarrhea develops.

Please see brief summary of full Prescribing Information on next page.

DERMIK®

© 2008 sanofi-aventis U.S. LLC

sanofi-aventis

US.CLI.08.04.003